Abstract. RhoA regulates cell proliferation, migration, angiogenesis and gene expression. Altered RhoA activity contributes to cancer progression. The present study investigated the effects of RhoA knockdown on the regulation of ovarian cancer biological behavior in vitro and in nude mice. The expression of RhoA was knocked down using a lentivirus carrying RhoA short hairpin RNA (shRNA) in ovarian cancer cells and was confirmed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis. The altered ovarian cancer biological behaviors were assayed by cell viability, terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling (TUNEL), migration, invasion, and nude mice tumorigenicity assays, while the altered gene expression was detected by RT-qPCR and western blot analysis. The results showed that lentivirus-carrying RhoA shRNA significantly suppressed RhoA expression in ovarian cancer cells, which suppressed tumor cell viability, migration, invasion and adhesion in vitro. RhoA silencing also inhibited the tumorigenicity of ovarian cancer cells in nude mice, which was characterized by the suppression of tumor xenograft formation and growth and induction of tumor cell apoptosis. The results of the present study demonstrated that knockdown of RhoA expression had a significant antitumor effect on ovarian cancer cells in vitro and in nude mice, suggesting that RhoA may be a target for the development of a novel therapeutic strategy in the control of ovarian cancer.
Introduction
Epithelial ovarian carcinoma is a significant health problem in women, accounting for ~160,000 cancer-related mortalities in 2010 worldwide (1) . Ovarian cancer is especially more common in industrialized nations, with the exception of Japan (1) , and the risk factors include hormone therapy after menopause, gene mutations (BRCA1 or BRCA2), tobacco smoking and obesity. The risk also increases with age but decreases with the number of pregnancies (2) (3) (4) . Most ovarian types of cancer are diagnosed at the advanced stages of disease and lead to a poor prognosis (5) . Despite surgical resection coupled with systemic chemotherapy and radiotherapy, the 5-year survival rate of ovarian cancer remains ~30%, and most patients succumb to this disease due to tumor recurrence and metastasis (6) . Thus, our research efforts on ovarian cancer, as with most other cancer types, should focus on controlling cancer metastasis, which includes several essential steps, i.e., tumor cell proliferation, migration, invasion, adhesion, and formation of metastasis in adjacent or distant organs or tissues (7, 8) . At the gene level, RhoA, a member of the Ras superfamily, acts as a molecular switch to promote cell mobility and, therefore, to participate in tumor progression. Specifically, RhoA activation can lead to a diverse set of biological responses, including cell motility, proliferation, apoptosis inhibition, cell cycle progression, invasion, and metastasis of tumor cells (9) (10) (11) (12) . Accumulating evidence has shown that RhoA activity is upregulated in most human carcinogenesis (13, 14) and tumor progression (15, 16) . Thus, RhoA may be a novel molecular target for controlling cancer metastasis.
It was previously demonstrated that the negative regulation of RhoA translation and signaling affected cell morphogenesis (17) , and the knockdown of RhoA expression using adenovirus-mediated RNA interference inhibited the proliferation and invasive ability of lung, gastric and colorectal cancer cells in vitro (18, 19) . Thus, in the present study, we utilized a lentivirus-carrying RhoA short hairpin RNA (shRNA) to knock down RhoA expression in a highly invasive epithelial ovarian cancer cell line and then assessed the altered biological behaviors in vitro and in nude mice.
Materials and methods
Cell lines and culture. The human HO8910 epithelial ovarian cancer cell line and human 293FT embryonic kidney cell line were obtained from the Zhongshan University Laboratory Animal Center (Guangzhou, China). HO8910 cells were grown in Roswell Park Memorial Institute (RPMI)-1640 medium (Invitrogen-Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA), while 293FT cells were cultured in Dulbecco's modified Eagle's medium supplemented with 4.5 g/l glucose (PAA Laboratories, Pasching, Austria), 10% heat-inactivated FBS (Hyclone), 100 U/ml penicillin and 100 µg/ml streptomycin (both from Invitrogen-Life Technologies) in a humidified incubator containing 5% CO 2 at 37˚C.
Establishment of stable RhoA-knockdown (RhoA-KD) tumor cells using a lentivirus-carrying RhoA shRNA. A lentiviral expression vector carrying RhoA shRNA was obtained from GeneCopoeia (Rockville, MD, USA), and the target sequence of RhoA cDNA was 5'-GAAGGCAGAGATATGGCAA-3'. A negative control vector was provided by GeneCopoeia, designated as Lenti-RhoA-NC. Lenti-RhoA-sh and Lenti-RhoA-NC vectors contained enhanced green fluorescent protein (eGFP) cDNA. The recombinant and control lentivirus were then produced via the co-transfection of 293FT cells with the Lenti-Pac™ HIV Expression Packaging kit (GeneCopoeia), and the virus-containing supernatant was harvested at 48 and 72 h post infection. To stably establish the RhoA-knockdown HO8910 subline, cells were grown and infected with lentivirus at a multiplicity of infection of 50, and the infection efficiency was directly measured by the detection of eGFP expression in cells by fluorescence microscopy. The cells were grown in medium containing 1.5 µg/ml puromycin (Invitrogen) for 20 days. After reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis confirmation of RhoA knockdown, RhoA shRNA-lentivirus-infected cells were named as RhoA-KD cells, whereas the control Lenti-RhoA-NC-infected cells were designated as mock cells.
RT-qPCR.
Total cell RNA was isolated from ovarian cancer cells using TRIzol reagent (Invitrogen-Life Technologies) and reverse transcribed into cDNA using the PrimeScript RT-PCR kit (Takara Bio Inc., Shiga, Japan), according to the manufacturer's instructions. The primers for the human RhoA gene were: forward, 5'-TTCCATCGACAGCCCTGATAGTTTA-3' and reverse, 5'-CACGTTGGGACAGAAATGCTTG-3'; while GAPDH was used as the internal control with the primers: forward, 5'-GCACCGTCAAGGCTGAGAAC-3' and reverse, 5'-TGGTGAAGACGCCAGTGGA-3'. PCR amplification and real-time fluorescence signaling monitoring was conducted using a Stratagene fluorescence quantitative PCR instrument according to a previous study (20) .
Protein extraction and western blot analysis. Cell lysis was performed using RIPA lysis buffer from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), and the protein concentration was measured using the Bradford method with the BCA protein assay kit (Pierce Biotechnology, Rockford, IL, USA). For western blot analysis, equal amounts of protein extracts (30 µg) were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred onto 0.45-µm polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The membranes were blocked in 5% non-fat dry milk solution in Tris-based saline Tween-20 (TBST) for 1 h and then incubated at 4˚C overnight with a polyclonal rabbit anti-RhoA antibody at a dilution of 1:100 (no. sc-179; Santa Cruz Biotechnology, Inc.) or a rabbit anti-β-actin antibody at a dilution of 1:1,000 (no. AP0060; Bioworld Technology, Louis Park, MN, USA) in TBST containing 5% non-fat dry milk, followed by incubation with a secondary horseradish peroxidase-conjugated anti-rabbit antibody (no. BS13278; Bioworld Technology) at a dilution of 1:5,000 in TBST containing 5% non-fat dry milk for 1 h at room temperature. The target protein bands were visualized using an enhanced chemiluminescence detection system (Pierce Biotechnology) and quantified using Image J 1.44p software (National Institutes of Health, Bethesda, MD, USA).
Cell viability assay. The altered cell viability after RhoA expression was knocked down in ovarian cancer cells was assayed by the cell viability 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay as previously described (21) . Stable RhoA-knockdown or control shRNA-infected cells were seeded in 96-well plates at a density of 5x10 3 cells/well and grown for up to 5 days. At the end of each experiment, 1 µl of MTT solution (Sigma-Aldrich, St. Louis, MO, USA) was added into each well and the plates were incubated for an additional 4-h at 37˚C. Then, 100 µl of dimethyl sulfoxide (DMSO) was added into each well to dissolve formazan by agitation for 10 min. The absorbance values (A) of cells were measured at a wavelength of 492 nm using a microplate reader. The experiments were performed in 5 wells and were repeated at least three times. The data were summarized as a percentage of the control using the formula: (OD RhoA /OD control ) x 100, where OD RhoA and OD control were the optical densities in RhoA-knockdown and negative control cultures, respectively.
Cell migration and invasion assay. Tumor cell migration and invasion ability were assayed using a 24-well Transwell chamber system with an 8-µm pore size polycarbonate membrane (Corning Life Sciences, Corning, NY, USA), as previously described (22, 23) . The difference between the tumor cell migration and invasion ability experiments was that the polycarbonate membrane was either pre-coated or not with Matrigel (30 µl, diluted at 1:3 with cell culture medium; BD Biosciences, San Jose, CA, USA). For the two assays, the cells were starved for 24 h and collected. Cells (5x10 4 ) in 200 µl of growth medium containing 0.5% bovine serum albumin (BSA; Sigma-Aldrich) were then placed in the upper chamber. The lower chamber was filled with 600 µl of growth medium containing 20% FBS, and the cells were cultured at 37˚C for 48 h. At the end of the experiments, the cells on the upper surface of the filter were removed using a cotton swab, while the cells that migrated or invaded through the filter or Matrigel-coated filter on the lower surface were fixed with 4% neutral-buffered formalin and stained in 0.01% crystal violet solution. The cell numbers were counted in 5 fields (up, down, middle, left and right; magnification x200) for each chamber, and the results were presented as the mean value ± standard deviation (SD). The experiment was performed in triplicate and repeated three times.
Cell adhesion assay. The cell adhesion ability was assayed using a 96-well plate that was pre-coated with 30 µl of Matrigel (diluted at 1:3 with growth medium). Particularly, cells were seeded on the plate and incubated in growth medium containing 0.1% BSA overnight. The following day, the cells were washed three times with serum-free medium, resuspended at a concentration of 1x10 6 /ml in serum-free medium, seeded into each well (100 µl/well), and then incubated at 37˚C for 1 h. Subsequently, the detached cells were washed away with phosphate-buffered saline (PBS), 10 µl of MTT solution was added to each well containing attached cells, and the plates were incubated at 37˚C for 4 h. DMSO (100 µl) was added into each well to dissolve formazan, and the absorbance value was measured at a wavelength of 492 nm using a microplate reader. The data were summarized and presented as the mean value ± SD, and the tumor cell adhesion rate was calculated using the following formula: relative adhesion rate (%) = (A 492 of experimental group/A 492 of the control group) x 100%. Each experiment was performed in triplicate and repeated three times.
Tumor cell intraperitoneal tumorigenicity assay in nude mice. Athymic nude female BALBC/c mice (4-6 weeks old, 14.96±0.96 g, animal protocol number: 0113061) were obtained from the Guangdong Medical Laboratory Animal Center (Guangzhou, China) [registration no. SCXK(YUE)2008-0002], maintained in specific pathogen-free, temperature-controlled isolation conditions, and fed with sterilized food and autoclaved water. Animal breeding, care, and experimental procedures were approved by the Ethics and Human Committee of Guangzhou Medical University and carried out strictly in accordance with the related regulations on the use of experimental animals.
To evaluate tumor cell peritoneal metastasis ability, 21 athymic nude female BALBC/c mice were randomly assigned to three groups (n=7 per group): i) RhoA-KD xenograft, ii) mock xenograft, and iii) parental xenograft groups. Cells in the logarithmic growth phase were collected and washed twice with PBS. Cells (5.0x10 6 /mouse) in 200 µl of serum-free medium with a survival rate of >95% (assessed using trypan blue staining) were injected into the peritoneal cavity of each mouse. The mice were monitored every 2 days and sacrificed 28 days after tumor cell inoculation. The abdominal circumference and ascetic volume were measured. The number of tumor lesions and disseminated tumors were counted, and the tumor nodules were excised for histopathology, RT-qPCR, western blot analysis, immunohistochemical staining, and terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling (TUNEL) assays. The liver, spleen, lung, and renal tissues were taken and used for the histopathological analysis of tumor metastasis.
Histopathology and immunohistochemistry.
Mouse tumor tissues were fixed in 4% paraformaldehyde for 24 h and embedded in paraffin. Tissue sections (4 µm) were prepared and stained with hematoxylin and eosin. The consecutive sections were used for immunohistochemical staining.
Specifically, the sections were dewaxed in toluene, rehydrated, permeabilized in citrate buffer (pH 6.0), and quenched by 3% H 2 O 2 for 15 min to inhibit any endogenous peroxidase activities. The sections were then incubated overnight at 4˚C with a polyclonal rabbit anti-RhoA antibody (diluted at 1:100). The following day, the sections were washed with PBS three times and then incubated with a biotinylated goat anti-rabbit IgG (Dako, Glostrup, Denmark), followed by peroxidase-conjugated streptavidin. The colorimetric reaction was performed using diaminobenzidine, and the sections were counterstained with hematoxylin. Immunostained sections were evaluated by two independent observers who were blinded to the tissue identity. The staining was scored as positive vs. negative when ≥10% tumor cells were positively stained with the polyclonal rabbit anti-RhoA antibody. Statistical analysis. Data were presented as mean ± SD. Statistical analysis was performed using SPSS 13.0 statistical software (SPSS, Inc., Chicago, IL, USA). Differences among different groups were assessed using one-way analysis of variance, and differences between two groups were assessed using the Student-Newman-Keuls (SNK) test. P<0.05 was considered statistically significant.
Results
Stable knockdown of RhoA expression in ovarian cancer cells using a lentivirus-carrying RhoA shRNA. In the present study, we assessed the role of RhoA knockdown in ovarian cancer cells. HO8910 cells infected with lentivirus for 48 h showed an infection efficiency of 60% by fluorescence microscopy (Fig. 1A) . After the cells were cultured in puromycin (1.5 µg/ml)-containing growth medium for 20 days, stable RhoA-KD and mock ovarian cancer cell populations were successfully generated (Fig. 1A) . Although these cell populations were cultured and passaged >10 times, the eGFPpositive expression in the cells remained >98%. The RT-qPCR and western blot analysis confirmed that the RhoA-KD cells had a significantly decreased expression of RhoA mRNA and protein (Fig. 1B and C, P<0 .05). Moreover, there was no difference in the RhoA expression between parental HO8910 cells and the mock cells (Fig. 1B and C, P>0 .05).
Effects of RhoA knockdown on the regulation of HO8910 cell biological behaviors in vitro.
After the stable RhoA-knockdown ovarian cancer cell population was obtained, we first assayed the effects of RhoA silencing on the regulation of tumor cell viability. As shown in Fig. 2A , although there was not a statistical difference in the cell viability among the parental, mock, and RhoA-KD cell cultures on day 1 (P>0.05), the cell viability of the RhoA-KD cultures was significantly attenuated between day 2 and 5 (P<0.05). By contrast, there was no difference in cell viability between the parental HO8910 and mock tumor cells (P>0.05). Moreover, the tumor cell migration and invasion assays showed that the knockdown of RhoA expression reduced the tumor cell migration and invasion abilities compared with the mock and parental HO8910 cells (P<0.05), whereas the parental HO8910 and mock cells showed similar migration and invasion abilities (Fig. 2B and C, P>0.05) .
Cancer cell adhesion to the peritoneum is a crucial process and the initial step during ovarian cancer peritoneal metastasis. Therefore, we assessed the effects of the knockdown of RhoA expression on the regulation of tumor cell adhesion. As shown in Fig. 3 , the tumor cell adhesion was markedly decreased after RhoA knockdown compared to that of the parental HO8910 and mock cells (P<0.05). However, the mock and parental HO8910 cells showed similar cell adhesion activities (P>0.05).
Effects of RhoA knockdown on the regulation of HO8910 cell biological behaviors in nude mice.
We assessed the in vivo effect of RhoA silencing in nude mice. We found that 10 days after tumor cell inoculation, the mice with parental or mock cell injections exhibited gradually decreased activity and appeared sluggish, but their abdominal circumference was obviously increased. By contrast, the nude mice with the RhoA-KD cell injection were generally in good condition and their abdominal circumference was gradually increased compared to the remaining two groups (Fig. 4A, P<0.05) . Moreover, when the mice were sacrificed at 4 weeks post-inoculation, the tumor formation rate was 71.4% (5/7) in the RhoA-KD group compared to 100% (7/7) in the remaining two groups. The volume of ascites, number of tumor lesions, total number of disseminated tumor nodules, and tumor weight were all significantly smaller in the RhoA-KD group than in the remaining two groups (Fig. 4B, P<0 .05). However, there was no statistically significant difference in tumor growth between the parental and mock groups (P>0.05). In addition, as shown in Fig. 5A , there were more necrotic and apoptotic regions found in tumors with RhoA knockdown than in the parental and mock groups. We performed a TUNEL assay to detect the apoptotic level in these tumor xenografts and found that the apoptotic index was significantly higher in the RhoA-KD group than in the parental and mock groups (Fig. 5E, P<0 .05). However, there was no statistically significant difference observed between the parental and mock groups (Fig. 5E, P>0.05) .
We confirmed RhoA knockdown in the mouse tumor xenografts using RT-qPCR, western blot analysis and immunostaining of RhoA mRNA and protein, respectively. The results showed that the RhoA mRNA level was significantly reduced in the RhoA-KD group, compared to the parental and mock groups (Fig. 5B, P<0.05) . Similarly, the RhoA protein level was significantly reduced in the RhoA-KD group compared with the parental and mock groups (Fig. 5C and D, P<0 .05). However, there was no significant difference of RhoA expression between the parental and mock groups (P>0.05). 
Discussion
Epithelial ovarian cancer is frequently diagnosed at the advanced stages of disease. Thus, it is a lethal gynecological malignancy and only 5-30% of ovarian cancer patients survive for 5 years (6, 24) . Tumor peritoneal metastasis occurs most frequently (6, 24) . In the present study, we targeted RhoA in ovarian cancer cells to further assess the role of RhoA knockdown in the regulation of ovarian cancer cell biological behaviors in vitro and in a nude mouse model. We found that . The results show that the abdominal circumference from the RhoA-KD-bearing mice was much smaller than that of the parental and mock groups (P<0.05), whereas there was no significantly difference between the mock and parental groups (P>0.05). (B) Measurement of tumor burdens. Tumor cells were disseminated in the abdominal cavities of the three groups of nude mice (data not shown). Numerous tumor nodules were disseminated on the peritoneal surface, stomach, diaphragm, colic omentum, mesentery, liver, spleen or kidney of the parental and mock groups, whereas few tumor nodules were shown on the peritoneal surface and around the radix of mesentery in the RhoA-KD group. RhoA knockdown significantly reduced tumor cell viability, migration, invasion, and adhesion abilities in vitro and inhibited tumor cell settling in the abdominal cavity and tumor formation in nude mice. The residual tumor xenografts showed necrosis and apoptosis after RhoA knockdown. The results of the present study confirmed RhoA activity in ovarian cancer. Future studies may target RhoA activity as a novel strategy to treat ovarian cancer patients.
RhoA is a member of the Ras gene superfamily of small GTPases. The biological function of RhoA is controlled by the cycling between the active GTP-bound and inactive GDP-bound states (25) . Early evidence has shown that RhoA is able to modulate cell adhesion, contraction, mobility and degradation of the extracellular matrix. However, more recent studies have clearly demonstrated that RhoA affects cell proliferation, angiogenesis, gene expression and tumor cell invasion and metastasis (26, 27) . For example, Rho proteins must be present for cells to progress through the G1 phase of the cell cycle (28) . In experimental models of carcinogenesis, aberrant RhoA activation induced cell growth, transformation, invasion and metastasis (29) (30) (31) (32) . Molecularly, RhoA regulates the activities of multiple transcription factors, such as ROCK, Cdc42 and Rac1, most of which are involved in cancer (10) . The upregulation of RhoA expression or activity has been associated with tumor progression (15) , whereas the downregulation of RhoA expression or activity has been shown to promote apoptosis of gastric cancer cells and inhibit the growth and invasion of gastric cancer cells in vitro (19) . Furthermore, factors such as epidermal growth factor and lysophosphatidic acid, are able to activate RhoA protein (29, 32) , further indicating the role of RhoA in tumorigenesis.
A previous study has shown that RhoA expression was significantly higher in metastatic omentum than in ovarian cancer, benign tumors, and normal fallopian tube epithelium and is associated with poor tumor differentiation and advanced stages of ovarian cancer (33) . In addition, an in vitro study has demonstrated that inhibition of the Rho/ROCK pathway enhanced the efficacy of cisplatin in human ovarian cancer cells (34) . By contrast, Rho expression was higher in patients who did not respond to chemotherapy (35) . In the present study, the results on RhoA knockdown in ovarian cancer cells in vitro supported the previous findings (15, 19) . Our results using the nude mouse intraperitoneal tumorigenicity model specifically showed that RhoA knockdown was able to suppress tumor formation and growth in the abdominal cavity, which is the site where ovarian cancer frequently spreads. A recent review indicated that RhoA is a therapeutic target for ovarian cancer (36) , while another study showed that the overexpression of RhoA enhanced peritoneal dissemination and that RhoA suppression with lovastatin may be a useful therapy for ovarian cancer (37) .
In the present study, shRNA, made of a tight hairpin turn of RNA sequences, was used to silence the target gene expression via RNA interference, which is a well-established technique to inhibit gene expression, typically by causing the destruction of specific mRNA molecules with high efficiency and specificity as well as low toxicity (38) . In recent years, lentivirus-mediated shRNA has been used successfully in vitro and in vivo and has shown great promise in the field of cancer therapy (39) . Thus, in the present study, we used this technique to knock down RhoA expression in ovarian cancer HO8910 cells, a highly invasive human ovarian cancer cell line with a high level of RhoA expression (17) . The results have shown that this lentivirus may silence RhoA expression with high efficiency. However, our results are preliminary and a proof-of-principle study as the side effects of this lentivirus in vivo were not assessed. In addition, we did not examine any molecular events after RhoA knockdown. Thus, future studies should focus on the underlying mechanisms of the antitumor effects in RhoA-knockdown tumor cells.
